Catalent Marks 40 Years in Japan with New Investments and Country Leader - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Marks 40 Years in Japan with New Investments and Country Leader



Catalent now in its 40th year of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products in the Japanese market and has appointed Tadahiro Matsumura as Country Leader. Based in Catalent’s Tokyo office, Matsumura will be responsible for driving growth through business development activities in Japan and the surrounding region.

In addition, the company has opened a laboratory at its Kakegawa, Japan site to provide proof-of-concept support and feasibility studies for Catalent’s Zydis Orally Dispersible Tablet (ODT) technology and will also expand manufacturing capacity for its OptiGel Micro softgel technology. Zydis ODT is a freeze-dried oral dosage form that disperses in the mouth, requiring no water. The new Zydis laboratories, which will be officially opened as part of the 40th anniversary celebrations in September, is being constructed within the existing 107,000 square-foot Kakegawa facility. Catalent’s OptiGel Micro Technology uses a droplet, streamline flow that results in spherical capsules. These capsules can be sized from 1-7mm, which allows for smaller capsules to be produced when compared to the traditional rotary die process.

Source: Catalent

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here